Targeted therapies for malignant salivary gland tumours have changed the treatment paradigm and therapy approaches. Better outcomes are now feasible. Choosing the treatment method requires a clear classification of the lesions. The authors of this paper reviewed the World Health Organization (WHO) classification for salivary gland pathologies from 1972 to 2022. The current (2022) classification provides insight based on the molecular basis of lesions. This has led to the evolution of classification and the introduction of new entities and reclassification of existing lesions. The authors predict that in future, genetic alterations will play a big role in the identification of salivary gland pathologies and the alterations will be prognostic and predictive biomarkers as well as serving as targets for therapies. Exciting times ahead!